References
- Slamon D. J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. New Eng. J. Med. 2001; 344: 783–792
- O'Shaughnessy J., Miles D., Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J. Clin. Oncol. 2002; 20(12)2812–2823
- Chao T.-C., Wang J.-C., Yen C.-C., et al. A dose-escalating pilot study of sterically stabilized pegylated liposome doxorubicin (Lipo-Dox®) in patients with metastatic breast cancer. Cancer Invest., (this issue)
- Coates A., Gebski V., Stat M., et al. Improving the quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N. Engl. J. Med. 1987; 317: 1490–1497
- Wigler N., Inbar M., O'Brien R., et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal dosxorubicin (Caelyx, Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: 45a, (abstract 177)
- Wasserheit C., Downey A., Sorich J., et al. A phase I study of taxotere and doxil in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 1999; 18: 642
- Sparano J., Malik U., Rajdev L., et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J. Clin. Oncol. 2001; 19: 3117–3225
- Safra T., Muggia F., Jeffers S., et al. Pegylated liposomal doxorubicin (DOXIL): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000; 11: 1029–1033
- Hamilton A., Biganzoli L., Coleman R., et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer. Ann. Oncol. 2002; 13: 910–918